Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant anti-RANKL monoclonal antibody
- Development stage
- Phase 1
- Lead developer
- Jiangsu Pacific Meinuoke Bio Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Recombinant anti-RANKL monoclonal antibody is a biosimilar of denosumab (Prolia) developed by Jiangsu Pacific Meinuoke Biopharmaceutical. It is a fully human monoclonal antibody that targets receptor activator of nuclear factor kappa-B ligand (RANKL). By binding to RANKL, the antibody prevents it from activating its receptor, RANK, on the surface of osteoclasts and their precursors. This inhibition of the RANKL/RANK pathway prevents osteoclast formation, function, and survival, thereby reducing bone resorption and increasing bone density. The drug is currently in Phase 1 clinical development in China for the treatment of postmenopausal osteoporosis in patients at high risk of fracture.
- Other names
- recombinant anti-RANKL monoclonal antibody (Jiangsu Pacific Meinuoke)重组抗RANKL单克隆抗体
02
Targets
RANKL (Receptor Activator for Nuclear Factor-kappa B Ligand)
Beyond the preview
Go deeper on recombinant anti-RANKL monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant anti-RANKL monoclonal antibody.